Lixte Biotechnology switches director compensation from cash to stock options for Q2-Q4 2024 to preserve cash

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.
Board Compensation Plan amended: non-officer directors will receive stock options for Q2, Q3, Q4 2024 in lieu of cash.
Options vest immediately, expire in 5 years; exercise price based on quarter-end closing market price.
Change intended to preserve cash; Board and Compensation Committee may extend beyond Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.